CellEctric Biosciences

Executive Summary

CellEctric Biosciences, an Austrian biotech founded in 2018, has developed a novel electroporation-based platform that uses selective electromagnetic fields to selectively lyse human cells in complex biological samples while leaving pathogens intact. This technology addresses a critical bottleneck in infectious disease diagnostics—sample preparation—by enabling faster and more accurate detection of pathogens, particularly in sepsis. The company’s initial focus is on improving sepsis diagnostics, where rapid and precise identification of causative pathogens can significantly impact patient outcomes. By streamlining the sample processing step, CellEctric’s platform has the potential to reduce time-to-diagnosis from hours to minutes, enhance sensitivity, and lower the overall cost of testing. The technology is versatile and could be extended to other infectious diseases and cell manipulation applications. Despite being in an early stage with limited publicly available details on funding or commercial traction, the company’s innovative approach addresses a clear unmet need. If successfully validated and commercialized, CellEctric could play a key role in advancing diagnostic capabilities in critical care settings.

Upcoming Catalysts (preview)

• TBDCompletion of prototype validation for sepsis diagnostics60% success
• TBDFirst clinical partnership or pilot study announcement50% success
• TBDRegulatory submission for CE marking or equivalent40% success